



PATIENT INFORMATION

Name: _____ DOB: _____ Gender: M F Last 4 of SSN: _____
 Address: _____ City: _____ State: _____ Zip: _____
 Phone: _____ Alt. Phone: _____ Caregiver: _____
 Email: _____ Height: _____ Weight: _____ Allergies: No known See Attached Charts Other: _____

PRESCRIBER INFORMATION

Name: _____ NPI: _____ DEA # _____
 Address: _____ City: _____ State: _____ Zip: _____
 Phone: _____ Fax: _____ Office Contact: _____

Statement of Medical Necessity (Please Attach All Medical Documentation)

Date of Diagnosis: _____ Does Patient Have Latex Allergy: Yes No Patient Also Using Topical Steroids: Yes No
 Diagnosis ICD-10: L20.9 Other: _____ TB Test: Positive Negative Hep B Ruled Out: Yes No
 Assessment: Face Chin Neck Legs Hands Wrists Other: _____ ISGA EASI BSA

Prior Failed Treatments	Drug Name & Length of Time
<input type="radio"/> Topicals	_____
<input type="radio"/> Methotrexate	_____
<input type="radio"/> Oral Meds	_____
<input type="radio"/> Biologics	_____
<input type="radio"/> UVA	_____
<input type="radio"/> UVB	_____
<input type="radio"/> Other	_____

Injection Training	Product Delivery
<input type="radio"/> Pharmacist to Provide Training	<input type="radio"/> Patients Home
<input type="radio"/> Patient Trained in MD Office	<input type="radio"/> Physician's Office
<input type="radio"/> Manufacturer Nurse Support	<input type="radio"/> Pharmacy to Coordinate

PRESCRIPTION INFORMATION (Please be sure to choose both induction and maintenance doses when applicable)

Drug	Strength	Directions	Quantity/Refills	
<input type="radio"/> DUPIXENT	<input type="radio"/> 300mg/2mL Prefilled Syringe <input type="radio"/> 300mg/2mL Prefilled Pen <input type="radio"/> 200mg/1.14mL Prefilled Syringe <input type="radio"/> 200mg/1.14mL Prefilled Pen	Patients 6 months – 5 years of age		
		5 to <15kg	<input type="radio"/> Initial Dose: 200mg SIG: 1 injection SQ on Day 1 <input type="radio"/> Maintenance Dose: 200mg SIG: 1 injection SQ every 4 weeks, starting on Day 29	Q: 1 R: _____ Q: _____ R: _____
		15 to <30kg	<input type="radio"/> Initial Dose: 300mg SIG: 1 injection SQ on Day 1 <input type="radio"/> Maintenance Dose: 300mg SIG: 1 injection SQ every 4 weeks, starting on Day 29	Q: 1 R: _____ Q: _____ R: _____
		Patients 6 years – 17 years of age		
		< 30kg	<input type="radio"/> Initial Dose: Inject 600mg (two 300mg injections) SQ on Day 1 <input type="radio"/> Maintenance Dose: 300mg SIG: Inject 300 mg every 4 weeks	Q: 2 R: _____ Q: _____ R: _____
		30kg to <60kg	<input type="radio"/> Initial Dose: Inject 400mg (two 200mg injections) SQ on Day 1 <input type="radio"/> Maintenance Dose: 200mg SIG: Inject 200mg every other week	Q: 2 R: _____ Q: _____ R: _____
		≥ 60kg	<input type="radio"/> Initial Dose: Inject 600mg (two 300mg injections) SQ on Day 1 <input type="radio"/> Maintenance Dose: 300mg SIG: Inject 300mg SQ every other week	Q: 2 R: _____ Q: _____ R: _____

Prescriber Signature (I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services, and patient assistance programs)

Signature: _____ Date: _____
 Substitution Permitted

Signature: _____ Date: _____
 Dispense as Written

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patients coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.